Milestone Pharmaceuticals Inc. (MIST)Healthcare | Biotechnology | Montreal, Canada | NasdaqGS
2.10 USD
+0.01
(0.478%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.10 Short-term: ★★★★★ | Long-term: ★★★☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 18, 2026, 11:35 p.m. EDT
MIST is in a high-conviction short-term breakout phase driven by positive catalysts (analyst upgrades, earnings beat) and aggressive call speculation, but long-term value remains subjective due to persistent losses and no current dividend infrastructure. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.189089 |
| AutoARIMA | 0.193771 |
| AutoETS | 0.193772 |
| AutoTheta | 0.208405 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 20.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 139.762 |
| Revenue per Share | 0.018 |
| Market Cap | 247,101,280 |
| Forward P/E | -2.46 |
| Beta | 0.69 |
| Website | https://www.milestonepharma.com |
As of April 18, 2026, 11:35 p.m. EDT: Speculative sentiment is heavily skewed bullish with significant Call positioning relative to Puts. The 2026-05-15 expiration sees the highest volume of out-of-the-money (OTM) calls (474 contracts) compared to negligible put volume (2), indicating a strong momentum buy program. Despite higher implied volatility in Puts for near-term expirations (1.91 IV) versus Calls (1.19 IV) at the April 17 strike, the sheer volume of Calls at May and June expirations suggests traders are positioning for a move above current levels (OTM OI % combined is significantly higher for Calls). The presence of Iron Condors (OTM Puts with volume) at May and June strikes suggests traders are offering downside protection at elevated prices, betting on a continued rally or a sharp, short-term bottoming out followed by upside.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0792079 |
| Address1 | 1,111 Dr. Frederik-Philips Boulevard |
| Address2 | Suite 420 |
| All Time High | 27.95 |
| All Time Low | 0.625 |
| Ask | 2.14 |
| Ask Size | 51 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 3,677,780 |
| Average Daily Volume3 Month | 2,256,849 |
| Average Volume | 2,256,849 |
| Average Volume10Days | 3,677,780 |
| Beta | 0.685 |
| Bid | 2.09 |
| Bid Size | 34 |
| Book Value | 0.341 |
| City | Montreal |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.1 |
| Current Ratio | 8.006 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.16 |
| Day Low | 2.05 |
| Debt To Equity | 139.762 |
| Display Name | Milestone Pharmaceuticals |
| Earnings Call Timestamp End | 1,774,009,800 |
| Earnings Call Timestamp Start | 1,774,009,800 |
| Earnings Timestamp | 1,774,009,800 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -62,026,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.211 |
| Enterprise To Revenue | -8.484 |
| Enterprise Value | -13,115,858 |
| Eps Current Year | -0.645 |
| Eps Forward | -0.855 |
| Eps Trailing Twelve Months | -0.75 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6574 |
| Fifty Day Average Change | 0.4425999 |
| Fifty Day Average Change Percent | 0.2670447 |
| Fifty Two Week Change Percent | 107.92079 |
| Fifty Two Week High | 3.06 |
| Fifty Two Week High Change | -0.96000004 |
| Fifty Two Week High Change Percent | -0.3137255 |
| Fifty Two Week Low | 0.88 |
| Fifty Two Week Low Change | 1.2199999 |
| Fifty Two Week Low Change Percent | 1.3863635 |
| Fifty Two Week Range | 0.88 - 3.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,408,600,000 |
| Float Shares | 14,061,117 |
| Forward Eps | -0.855 |
| Forward P E | -2.4561403 |
| Free Cashflow | -28,903,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 38 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,546,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02398 |
| Held Percent Institutions | 0.27124 |
| Implied Shares Outstanding | 117,667,278 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. |
| Long Name | Milestone Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 247,101,280 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_36171059 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -63,058,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 248,277,954 |
| Number Of Analyst Opinions | 6 |
| Open | 2.12 |
| Operating Cashflow | -49,041,000 |
| Operating Margins | -11.16235 |
| Payout Ratio | 0.0 |
| Phone | 514 336 0444 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.1 |
| Post Market Time | 1,776,465,438 |
| Previous Close | 2.09 |
| Price Eps Current Year | -3.2558138 |
| Price Hint | 4 |
| Price To Book | 6.1583576 |
| Price To Sales Trailing12 Months | 159.83266 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.831 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.478468 |
| Regular Market Day High | 2.16 |
| Regular Market Day Low | 2.05 |
| Regular Market Day Range | 2.05 - 2.16 |
| Regular Market Open | 2.12 |
| Regular Market Previous Close | 2.09 |
| Regular Market Price | 2.1 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,278,004 |
| Return On Assets | -0.41085 |
| Return On Equity | -2.29653 |
| Revenue Per Share | 0.018 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 117,667,277 |
| Shares Percent Shares Out | 0.0718 |
| Shares Short | 8,453,485 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,424,060 |
| Short Name | Milestone Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0718 |
| Short Ratio | 4.14 |
| Source Interval | 15 |
| State | QC |
| Symbol | MIST |
| Target High Price | 8.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 6.5 |
| Target Median Price | 7.5 |
| Total Cash | 105,960,000 |
| Total Cash Per Share | 6.456 |
| Total Debt | 58,377,000 |
| Total Revenue | 1,546,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.886725 |
| Two Hundred Day Average Change | 0.21327496 |
| Two Hundred Day Average Change Percent | 0.11303977 |
| Type Disp | Equity |
| Volume | 1,278,004 |
| Website | https://www.milestonepharma.com |
| Zip | H4M 2X6 |